# A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

Source: https://onco.cc/trials/nct07392736/  
OnCo record `nct07392736` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Advenchen Laboratories, LLC, now recruiting.

## Summary

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT07392736 by Advenchen Laboratories, LLC, with 228 participants planned, started 2021-10-26 and due to reach its primary completion in 2029-11-07. Interventions recorded: AL8326 tablets and Toripalimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07392736
- Phase: 1/2
- Setting: A Phase I/IIa Clinical Trial of AL8326 Tablets Combined With Toripalimab in the Treatment of Advanced Recurrent or Metastatic Solid Tumors
- Sponsor: Advenchen Laboratories, LLC
- Enrolled: 228

## Sources

- ClinicalTrials.gov NCT07392736: https://clinicaltrials.gov/study/NCT07392736

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [Advenchen Laboratories](https://onco.cc/companies/advenchen-laboratories/)

---
JSON: https://onco.cc/api/v1/entities/nct07392736.json